Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 31, Issue 7, Pages 1038-1046Publisher
SPRINGER
DOI: 10.1007/s00259-004-1571-4
Keywords
Y-90-DOTATOC; neuroendocrine tumours; receptor radionuclide therapy; somatostatin receptors
Ask authors/readers for more resources
Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue Y-90-[DOTA](0)-Tyr(3)-octreotide [Y-90-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
